This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Meulen, J.H.P. Articles by Habbema, J.D.F. Search for Related Content PubMed PubMed Citation Articles by van der Meulen, J.H.P. Articles by Habbema, J.D.F.

(Stroke. 1996;27:633-638.)
© 1996 American Heart Association, Inc.

Articles

Computed Tomographic Brain Scans and Antiplatelet Therapy After Stroke

A Study of the Quality of Care in Dutch Hospitals

J.H.P. van der Meulen, MD, PhD; M. Limburg, MD, PhD; A. van Straten, MSc J.D.F. Habbema, PhD

From the Departments of Clinical Epidemiology and Biostatistics (J.H.P. van der M.) and Neurology (M.L., A. van S.), Academic Medical Center, University of Amsterdam; and the Center for Clinical Decision Sciences, Department of Public Health, Erasmus University, Rotterdam (J.H.P. van der M., J.D.F.H.), Netherlands.

Correspondence to J.H.P. van der Meulen, Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam Zuidoost, Netherlands. E-mail j.vandermeulen@amc.uva.nl.

Background and Purpose We sought to develop a measure ("quality weight") that indicates the severity of a deviation from optimal care with respect to secondary prevention with antiplatelet treatment after stroke. We also sought to estimate the effects that efforts to improve the quality of secondary prevention may have on health outcome and healthcare costs in the Netherlands.

Methods First, we developed quality weights with decision analysis techniques. These quality weights express the excess risk of vascular events in the first 2 years after stroke compared with the optimal strategy (CT brain scan in all patients and aspirin in case of cerebral infarction). Second, these weights were applied in a follow-up study of 738 stroke patients older than 45 years. The number of stroke patients admitted to a hospital in 1991 in the Netherlands was used to estimate nationwide effects. We used data from 23 neurological departments and from the Information Center for Health Care in the Netherlands.

Results The 2-year excess risk of fatal and nonfatal vascular events caused by omitting a CT brain scan and giving aspirin to all patients is rather small (on average, 0.6%). The 2-year excess risk caused by not giving aspirin to a patient with cerebral infarction is much higher (4.1%). The follow-up study indicated that only 6% of the admitted patients had not been evaluated with a CT brain scan and that 14% of the patients with cerebral infarction proven by CT scan did not get antiplatelet treatment at discharge. Efforts to improve the quality of secondary prevention after stroke may prevent 74 vascular events annually in the Netherlands at an expense of 6200 Dutch guilders per prevented event (1 Dutch guilder=0.53 US dollar, 1991).

Conclusions Efforts to improve the quality of secondary prevention with antiplatelet treatment might reduce the number of new vascular events within the first 2 years after stroke by approximately 3%. The total costs related to the extra diagnostic and therapeutic activities are approximately 0.2% of the total annual hospital costs for acute stroke patients in the Netherlands (250 million Dutch guilders).

Key Words: antiplatelet therapy • computed tomography • hospitalization • Netherlands • quality of health care

This article has been cited by other articles:

				R. Luengo-Fernandez, A. M. Gray, and P. M. Rothwell Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature Stroke, February 1, 2009; 40(2): e18 - e23. [Abstract] [Full Text] [PDF]

				J. M. Wardlaw, J. Seymour, J. Cairns, S. Keir, S. Lewis, and P. Sandercock Immediate Computed Tomography Scanning of Acute Stroke Is Cost-Effective and Improves Quality of Life Stroke, November 1, 2004; 35(11): 2477 - 2483. [Abstract] [Full Text] [PDF]

				T. Sappok, A. Faulstich, E. Stuckert, H. Kruck, P. Marx, and H.-C. Koennecke Compliance With Secondary Prevention of Ischemic Stroke: A Prospective Evaluation Stroke, August 1, 2001; 32(8): 1884 - 1889. [Abstract] [Full Text] [PDF]

				R. Handschu, A. Garling, P. U. Heuschmann, P. L. Kolominsky-Rabas, F. Erbguth, and B. Neundorfer Acute Stroke Management in the Local General Hospital Stroke, April 1, 2001; 32(4): 866 - 870. [Abstract] [Full Text] [PDF]

				T. Hillen, R. Dundas, E. Lawrence, J. A. Stewart, A. G. Rudd, and C. D. A. Wolfe Antithrombotic and Antihypertensive Management 3 Months After Ischemic Stroke : A Prospective Study in an Inner City Population Stroke, February 1, 2000; 31(2): 469 - 475. [Abstract] [Full Text] [PDF]